1. Introduction
===============

Corrosion problems have received considerable attention due to their detrimental effects on materials that contribute to substantial economic losses and environmental pollution. The use of organic inhibitors is one of the most practical and environmentally-friendly methods to protect metals and alloys against corrosion, particularly at acid pHs that certainly damage the steel industrial infrastructure, relevant to overall economic behaviour as one determinant factor of the GNP. A number of heterocyclic organic compounds having either a delocalized set of electrons or just an electron pair on nitrogen, oxygen or sulfur heteroatoms, through which they adsorb on metallic surfaces, can block the active sites to decrease the rate of corrosion of steel, for example. Pyrimidines have various pharmaceutical applications as analgesic, antipyretic, antihypertensive and anti-inflammatory drugs, in pesticides, herbicides, plant growth regulators, and as organic calcium channel modulators \[[@B1-molecules-18-04613],[@B2-molecules-18-04613],[@B3-molecules-18-04613],[@B4-molecules-18-04613]\]. A perusal of the literature revealed that pyrimidine derivatives and the uracil and thymine nitrogen bases \[[@B5-molecules-18-04613],[@B6-molecules-18-04613],[@B7-molecules-18-04613],[@B8-molecules-18-04613],[@B9-molecules-18-04613],[@B10-molecules-18-04613],[@B11-molecules-18-04613],[@B12-molecules-18-04613],[@B13-molecules-18-04613],[@B14-molecules-18-04613],[@B15-molecules-18-04613],[@B16-molecules-18-04613]\] are efficient inhibitors to protect steel in acidic solutions \[[@B15-molecules-18-04613],[@B17-molecules-18-04613]\]. 1,2,3-Triazoles have been the subject of considerable research, mainly due to their usefulness in synthetic organic chemistry and also due to their variety of interesting biological activities, forming part of the scaffolds of antibacterial and antituberculosis agents \[[@B18-molecules-18-04613],[@B19-molecules-18-04613]\], neuraminidase inhibitors \[[@B20-molecules-18-04613]\], anticancer compounds \[[@B21-molecules-18-04613],[@B22-molecules-18-04613],[@B23-molecules-18-04613],[@B24-molecules-18-04613]\], antiviral agents \[[@B25-molecules-18-04613],[@B26-molecules-18-04613],[@B27-molecules-18-04613]\], analgesic compounds \[[@B28-molecules-18-04613]\], fungicidal activity \[[@B29-molecules-18-04613],[@B30-molecules-18-04613],[@B31-molecules-18-04613]\], protein tyrosine phosphatase inhibitors \[[@B32-molecules-18-04613],[@B33-molecules-18-04613]\], and assorted biomolecules (nucleosides and nucleotides) \[[@B34-molecules-18-04613],[@B35-molecules-18-04613]\]. On the other hand, 1,2,3-triazoles have other applications, like in chemosensors \[[@B36-molecules-18-04613]\] and organocatalysts \[[@B37-molecules-18-04613]\]. Just as relevant to applications of 1,2,3-triazoles in the biological and pharmaceutical fields, these molecules belong to the heterocyclic compounds class, constituting an important category of organic inhibitors for corrosion protection of industrial alloys in different acidic solutions. Many substituted triazole compounds continue to be of scientific and engineering interest, and thus they have been studied in considerable detail as effective corrosion inhibitors for steel in acidic media \[[@B38-molecules-18-04613],[@B39-molecules-18-04613],[@B40-molecules-18-04613],[@B41-molecules-18-04613],[@B42-molecules-18-04613],[@B43-molecules-18-04613],[@B44-molecules-18-04613],[@B45-molecules-18-04613],[@B46-molecules-18-04613],[@B47-molecules-18-04613],[@B48-molecules-18-04613],[@B49-molecules-18-04613],[@B50-molecules-18-04613],[@B51-molecules-18-04613],[@B52-molecules-18-04613],[@B53-molecules-18-04613],[@B54-molecules-18-04613],[@B55-molecules-18-04613],[@B56-molecules-18-04613],[@B57-molecules-18-04613]\]. In this context, we decided to explore the synthesis of some new 1,2,3-triazoleuracils and 1,2,3-triazolethymines and their anti-corrosion properties.

2. Results and Discussion
=========================

2.1. Synthesis
--------------

The dipropargyl uracil **3** was prepared from uracil (**1**) and propargyl bromide in the presence of DBU by refluxing the mixture in acetonitrile for 18 h. The TLC (CH~2~Cl~2~/MeOH 95:5 *v*/*v*) for the crude reaction mixture showed the formation of **3** (major product) and *N-*1-propargyluracil (minor product).

![Dialkylation of pyrimidine nucleobases **1**--**2** with propargyl bromide.](molecules-18-04613-g002){#molecules-18-04613-f002}

The desired product **3** was obtained in 79% yield before purification by column chromatography ([Scheme 1](#molecules-18-04613-f002){ref-type="scheme"}). These same conditions were used for the preparation of **4**, which was obtained in 70% yield from thymine ([Scheme 1](#molecules-18-04613-f002){ref-type="scheme"}). The second step of the synthesis was the preparation of 1,2,3-triazole nucleobases **5**--**14** through a Huisgen cycloaddition reaction between azides and the terminal alkynes. Based on the Fokin and Van der Eychen methodology \[[@B58-molecules-18-04613]\], it was decided to carry out a multicomponent Cu(I)-catalyzed click reaction for the preparation of the compounds \[[@B59-molecules-18-04613],[@B60-molecules-18-04613],[@B61-molecules-18-04613],[@B62-molecules-18-04613],[@B63-molecules-18-04613],[@B64-molecules-18-04613],[@B65-molecules-18-04613],[@B66-molecules-18-04613]\]. Initially, the reaction was tested by mixing dipropargyl uracil **3**, benzyl chloride and sodium azide in the presence of triethylamine and a catalytic amount of Cu(I) iodide \[[@B67-molecules-18-04613],[@B68-molecules-18-04613],[@B69-molecules-18-04613],[@B70-molecules-18-04613],[@B71-molecules-18-04613]\], and stirring at room temperature for 36 h, whereby compound **5** was obtained in 44% yield ([Table 1](#molecules-18-04613-t001){ref-type="table"}, entry 1). When the reaction was repeated using Cu(OAc)~2~•H~2~O as precatalyst \[[@B72-molecules-18-04613],[@B73-molecules-18-04613],[@B74-molecules-18-04613]\], sodium ascorbate as reducing agent, and 1,10-phenanthroline•H~2~O as ligand \[[@B67-molecules-18-04613],[@B75-molecules-18-04613]\] in EtOH-H~2~O at room temperature, compound **5** was obtained in 74% yield ([Table 1](#molecules-18-04613-t001){ref-type="table"}, entry 2). With these reaction conditions established, the remaining compounds **6**--**14** were prepared and obtained in good yields ([Table 1](#molecules-18-04613-t001){ref-type="table"}, entries 3-11).

molecules-18-04613-t001_Table 1

###### 

Multicomponent click reaction catalyzed by Cu(OAc)~2~•H~2~O.

  Entry   Compound   R^1^    R^2^   X    Yield ^a^ (%)
  ------- ---------- ------- ------ ---- ---------------
  1 ^b^   **5**      H       H      Cl   44
  2       **5**      H       H      Cl   74
  3       **6**      H       F      Cl   78
  4       **7**      H       Cl     Cl   71
  5       **8**      H       Br     Br   87
  6       **9**      H       I      Br   84
  7       **10**     CH~3~   H      Cl   64
  8       **11**     CH~3~   F      Cl   87
  9       **12**     CH~3~   Cl     Cl   74
  10      **13**     CH~3~   Br     Br   73
  11      **14**     CH~3~   I      Br   86

^a^ Isolated yields after purification; ^b^ The reaction was carried out employing 0.53 mmol of **3**, Cu(I) iodide (5 mol%), and NEt~3~ (3 eq.), stirring at room temperature for 36 h.

The structure of all compounds was confirmed by examination of their ^1^H- and ^13^C-NMR spectra, IR and mass spectra. The presence of the 1,4-disubstituted 1,2,3-triazole nucleobases was unequivocally established by means of the characteristic chemical shift values of the triazolyl hydrogens at 7.49--8.14 ppm and the chemical shift values for the carbon atoms of the triazole ring at 123.4--124.5 ppm for CH and 142.3--143.7 ppm for the quaternary carbon ([Table 2](#molecules-18-04613-t002){ref-type="table"}). These chemical shift values are completely consistent with those reported by Creary for 1,4-disubstituted 1,2,3-triazoles \[[@B76-molecules-18-04613]\].
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###### 

^1^H- and ^13^C-NMR chemical shifts (ppm) of the triazole ring in compounds **5**--**14**.

  Compound   R^1^    R^2^   H-5         C-5           C-4
  ---------- ------- ------ ----------- ------------- -------------
  **5**      H       H      7.49/7.62   123.4/123.7   142.3/143.4
  **6**      H       F      7.96/8.12   124.0/124.3   143.0/143.4
  **7**      H       Cl     7.98/8.14   124.2/124.5   143.0/143.4
  **8**      H       Br     7.98/8.13   124.2/124.5   143.0/143.4
  **9**      H       I      7.95/8.12   124.1/124.5   143.0/143.4
  **10**     CH~3~   H      7.49/7.62   123.5/123.7   142.6/143.5
  **11**     CH~3~   F      7.96/8.12   124.0/124.3   143.1/143.5
  **12**     CH~3~   Cl     7.50/7.64   123.5/123.7   142.8/143.7
  **13**     CH~3~   Br     7.50/7.65   123.5/123.7   142.8/143.7
  **14**     CH~3~   I      7.95/8.11   124.1/124.4   143.1/143.5

2.2. Corrosion Inhibition Efficiencies
--------------------------------------

We evaluated, using electrochemical means, the corrosion inhibition efficiencies of the first four compounds considered in this work. [Figure 1](#molecules-18-04613-f001){ref-type="fig"} depicts, as an example, the impedance measurements for both bare steel surfaces immersed in 1 M HCl (see [Figure 1](#molecules-18-04613-f001){ref-type="fig"}a), and the same system after adding 25 ppm of compound **3** to the acid media (see [Figure 1](#molecules-18-04613-f001){ref-type="fig"}b). The results of the analysis of the impedance data are shown in [Table 3](#molecules-18-04613-t003){ref-type="table"}. It is important to remark that all these compounds have corrosion inhibition efficiencies, IE, close to 90% at a rather low concentration value.

![Experimental impedance data, Nyquist plots, recorded in the systems a) API 5L X52/1 M HCl and b) API 5L X52/1 M HCl + 25 ppm of compound **3**.](molecules-18-04613-g001){#molecules-18-04613-f001}

molecules-18-04613-t003_Table 3

###### 

Electrochemical parameters obtained from experimental impedance data, see [Figure 1](#molecules-18-04613-f001){ref-type="fig"}, including the corrosion inhibition efficiencies, IE.

  Compound   Rs/Ω cm^2^   Rp/Ω cm^2^   C/µF   IE/%
  ---------- ------------ ------------ ------ ------
  Blank      2.4          30           310    \-
  1          2.5          242          94     88
  2          7.1          304          97     90
  3          2.0          163          167    82
  4          1.8          233          100    87

3. Experimental
===============

3.1. General
------------

Commercially available reagents and solvents were used as received. Flash column chromatography was performed on Kieselgel silica gel 60 (230--400 mesh). Melting points were determined on a Fisher-Johns apparatus and are uncorrected. IR spectra were recorded on a Bruker Alpha FT-IR/ATR spectrometer (Leipzig, Germany). NMR spectra (^1^H at 500 MHz, ^13^C at 125.76 MHz) were obtained with a JEOL ECA-500 (500 MHz) spectrometer (Tokyo, Japan). Chemical shifts (δ) are given in ppm downfield from Me~4~Si used as an internal reference; coupling constants are given in *J* (Hertz). High-resolution mass spectra (HRMS) were recorded on a JEOL JMS-SX 102a and Agilent-MSD-TOF-1069A spectrometers (Tokyo, Japan). The electrochemical impedance study was performed at room temperature using the IM6-ZAHNER electrochemical workstation (ZAHNER-Elektrik GmbH & Co.KG, Kronach, Germany), applying a sinusoidal ± 10 mV perturbation, within the frequency range of 100 KHz to 0.1 Hz to an electrochemical cell with three-electrode setup. A saturated Ag/AgCl mini-electrode was used as reference, with a graphite bar as counter electrode, while the working electrode was a steel sample of API 5L X52 with an exposed area of approximately 1 cm^2^, which was prepared using standard metallographic procedures. The corrosion inhibition efficiency (IE) was evaluated by means of Electrochemical Impedance Spectroscopy (EIS) in the API 5L X52/1 M HCl system containing 0 (blank) or 25 ppm of the inhibitor molecule. Simulation of the impedance data recorded was conducted by means of electrical equivalent circuits \[[@B17-molecules-18-04613]\] and the electrical parameters: Rs, solution resistance, Rtc, charge transfer resistance and C, the capacitance, were obtained in this way.

3.2. Product Synthesis and Characterization
-------------------------------------------

*1,3-Di(prop-2-ynyl)pyrimidine-2,4(1H,3H)-dione* (**3**). In a 100 mL round-bottom flask containing a magnetic stirrer and equipped with a reflux condenser, uracil (**1**, 1.12 g, 10 mmol) was suspended in dry acetonitrile (15 mL), 1,8-diazabicyclo\[5.4.0\]undec-7-ene (DBU, 3.3 mL, 3.35 g, 22 mmol) was added and the mixture stirred for a few minutes until a clear solution was obtained. Subsequently, propargyl bromide (80 wt. % in toluene, 2.22 mL, 2.97 g, 25 mmol) was added and the whole reaction mixture was heated at reflux for 18 h. The acetonitrile was evaporated under vacuum and CH~2~Cl~2~ (20 mL) was added. The organic phase was washed with aqueous NH~4~Cl solution (5%, 20 mL), dried with anhydrous Na~2~SO~4~ and concentrated under vacuum. The residue was purified by column chromatography (CH~2~Cl~2~) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to obtain 1.48 g (79% yield) of **3** as a white solid, m.p. 102--104 °C \[Lit. \[[@B77-molecules-18-04613]\] m.p. 105 °C\]. ^1^H-NMR (CDCl~3~): δ = 2.17 (t, *J* = 2.5 Hz, 1H, ≡C-H), 2.50 (t, *J* = 2.6 Hz, 1H, ≡C-H), 4.59 (d, *J* = 2.6 Hz, 2H, CH~2~), 4.68 (d, *J* = 2.5 Hz, 2H, CH~2~), 5.83 (d, *J* = 8.0 Hz, 1H, CH), 7.46 (d, *J* = 8.0 Hz, 1H, NCH). ^13^C-NMR (CDCl~3~): δ = 30.5 (CH~2~), 38.0 (CH~2~), 70.9 (≡C-H), 75.9 (C), 76.0 (≡C-H), 77.9 (C), 102.4 (CH), 140.8 (NCH), 150.5 (N~2~C=O), 161.7 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,289, 3,259 (≡C-H), 3,117, 3,090, 3,006, 2,983, 2,949, 2,124 (C≡C), 1,708 (C=C), 1,648 (NC=O, N~2~C=O), 1,540, 1,432. HRMS (ESI-TOF) calculated for C~10~H~8~N~2~O~2~+H^+^: 189.0658; Found: 189.0661.

*5-Methyl-1,3-di(prop-2-ynyl)pyrimidine-2,4-(1H,3H)-dione* (**4**). The procedure described above was followed to obtain compound **4**, employing thymine (**2**, 1.26 g, 10 mmol), DBU (3.3 mL, 22 mmol) and propargyl bromide (80 wt. % in toluene, 2.22 mL, 25 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 1.41 g (70% yield) of **4** as a white solid, m.p. 96--100 °C \[Lit. \[[@B77-molecules-18-04613]\] m.p. 101 °C\]. ^1^H-NMR (CDCl~3~): δ = 1.97 (d, *J* = 1.3 Hz, 3H, CH~3~), 2.17 (t, *J* = 2.5 Hz, 1H, ≡C-H), 2.47 (t, *J* = 2.6 Hz, 1H, ≡C-H), 4.57 (d, *J* = 2.6 Hz, 2H, CH~2~), 4.72 (d, *J* = 2.5 Hz, 2H, CH~2~), 7.26 (q, *J* = 1.2 Hz, 1H, NCH). ^13^C-NMR (CDCl~3~): δ = 13.2 (CH~3~), 30.7 (CH~2~), 37.6 (CH~2~), 70.8 (≡C-H), 75.4 (≡C-H), 76.4 (C), 78.1 (C), 110.9 (CCH~3~), 136.8 (NCH), 150.4 (N~2~C=O), 162.6 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,274, 3,260 (≡C-H), 3,072, 2,985, 2,931, 2,128 (C≡C), 1,700 (C=C), 1,657 (NC=O), 1,628 (N~2~C=O), 1,463. HRMS (ESI-TOF) calculated for C~11~H~10~N~2~O~2~+H^+^: 203.0815; Found: 203.0817.

*1,3-Bis((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)pyrimidine-2,4-(1H,3H)-dione* (**5**). In a 50 mL round-bottomed flask equipped with a magnetic stirrer, were added Cu(OAc)~2~•H~2~O (5 mg, 0.027 mmol, 5 mol%), 1,10-phenanthroline monohydrate (5 mg, 0.027 mmol, 5 mol%) and sodium L-ascorbate (107 mg, 0.54 mmol) in EtOH-H~2~O (6:4 *v*/v, 5 mL), followed by stirring for five minutes at room temperature. Subsequently, **3** (100 mg, 0.53 mmol), sodium azide (76 mg, 1.17 mmol) and benzyl chloride (0.13 mL, 1.17 mmol) were added to the reaction mixture, which was stirred during 36 h at room temperature (the product starts to precipitate after a few hours). Afterwards, H~2~O (15 mL) was added to the reaction mixture to complete precipitation of the product, which was filtered off, washed with H~2~O, then with hexane and dried under vacuum. The crude product was purified by column chromatography (CH~2~Cl~2~/EtOH 98:2 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 180 mg (74% yield) of **5** as a white solid, m.p. 171--172 °C. ^1^H-NMR (CDCl~3~): δ = 4.93 (s, 2H, CH~2~NC=O), 5.15 (s, 2H, CH~2~NC=O), 5.43 (s, 2H, NCH~2~Ph), 5.47 (s, 2H, NCH~2~Ph), 5.69 (d, *J* = 7.9 Hz, 1H, CH), 7.20--7.28 (m, 4H, ArH), 7.32--7.42 (m, 6H, ArH), 7.44 (d, *J* = 8.0 Hz, 1H, NCH), 7.49 (s, 1H, ArH, triazole), 7.62 (s, 1H, ArH, triazole). ^13^C-NMR (CDCl~3~): δ = 36.2 (CH~2~NC=O), 44.2 (CH~2~NC=O), 54.2 (NCH~2~Ph), 54.4 (NCH~2~Ph), 102.0 (CH), 123.4 (ArCH, triazole), 123.7 (ArCH, triazole), 128.2 (2×ArCH), 128.4 (2×ArCH), 128.8 (ArCH), 129.0 (ArCH), 129.1 (2×ArCH), 129.3 (2×ArCH), 134.2 (C~ipso~), 134.6 (C~ipso~), 142.3 (C~ipso~, triazole), 142.6 (NCH), 143.4 (C~ipso~, triazole), 151.2 (N~2~C=O), 162.6 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,133, 3,067, 3,012, 2,954, 1,700 (C=C), 1,650 (NC=O, N~2~C=O), 1,555, 1,496, 1,452, 1,434. HRMS (ESI-TOF) calculated for C~24~H~22~N~8~O~2~+H^+^: 455.1938; Found: 455.1939.

*1,3-Bis((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione* (**6**). The procedure described above (using the same quantities of Cu(OAc)~2~•H~2~O, 1,10-phenanthroline monohydrate, and sodium L-ascorbate) was followed to obtain the compound **6**, employing **3** (100 mg, 0.53 mmol), sodium azide (76 mg, 1.17 mmol) and 4-fluorobenzyl chloride (0.14 mL, 1.17 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/MeOH 90:10 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 203 mg (78% yield) of **6** as a white solid, m.p. 186--188 °C. ^1^H-NMR (DMSO-*d*~6~): δ = 4.95 (s, 2H, CH~2~NC=O), 4.97 (s, 2H, CH~2~NC=O), 5.48 (s, 2H, NCH~2~Ph), 5.53 (s, 2H, NCH~2~Ph), 5.73 (d, *J* = 7.9 Hz, 1H, CH), 7.13--7.19 (m, 4H, ArH), 7.31--7.37 (m, 4H, ArH), 7.80 (d, *J* = 7.9 Hz, 1H, NCH), 7.96 (s, 1H, ArH, triazole), 8.12 (s, 1H, ArH, triazole). ^13^C-NMR (DMSO-*d~6~*): δ = 36.3 (CH~2~NC=O), 44.1 (CH~2~NC=O), 52.4 (NCH~2~Ph), 52.5 (NCH~2~Ph), 101.0 (CH), 116.0 (d, *J*^2^~CF~ = 21.4 Hz, 2×ArCH), 116.2 (d, *J*^2^~CF~ = 21.4 Hz, 2×ArCH), 124.0 (ArCH, triazole), 124.3 (ArCH, triazole), 130.8 (d, *J*^3^~CF~ = 8.8 Hz, 2×ArCH), 130.9 (d, *J*^3^~CF~ = 8.8 Hz, 2×ArCH), 132.6 (d, *J*^4^~CF~ = 2.5 Hz, C~ipso~), 132.8 (d, *J*^4^~CF~ = 2.5 Hz, C~ipso~), 143.0 (C~ipso~, triazole), 143.4 (C~ipso~, triazole), 144.9 (NCH), 151.3 (N~2~C=O), 161.4 (d, *J*~CF~ = 243.8 Hz, C~ipso~), 162.5 (NC=O), 163.4 (d, *J*~CF~ = 243.8 Hz, C~ipso~). FT-IR/ATR ν~max~ cm^−1^: 3,126, 3,066, 3,012, 2,969, 1,705 (C=C), 1,657 (NC=O, N~2~C=O), 1,604, 1,544, 1,508, 1,453. HRMS (ESI-TOF) calculated for C~24~H~20~F~2~N~8~O~2~+H^+^: 491.1750; Found: 491.1751.

*1,3-Bis((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione* (**7**). The procedure described above (using the same quantities of Cu(OAc)~2~•H~2~O, 1,10-phenanthroline monohydrate, and sodium L-ascorbate) was followed to obtain compound **7**, employing **3** (100 mg, 0.53 mmol), NaN~3~ (76 mg, 1.17 mmol) and 4-chlorobenzyl chloride (198 mg, 1.23 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/EtOH 97:3 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 197 mg (71% yield) of the desired product **7** as a white solid, m.p. 185--187 °C. ^1^H-NMR (DMSO-*d~6~*): δ = 4.96 (s, 2H, CH~2~NC=O), 4.98 (s, 2H, CH~2~NC=O), 5.51 (s, 2H, NCH~2~Ph), 5.55 (s, 2H, NCH~2~Ph), 5.73 (d, *J* = 7.9 Hz, 1H, CH), 7.28 (d, *J* = 8.4 Hz, 2H, ArH), 7.30 (d, *J* = 8.3 Hz, 2H, ArH), 7.39 (d, *J* = 8.4 Hz, 2H, ArH), 7.40 (d, *J* = 8.4 Hz, 2H, ArH), 7.80 (d, *J* = 7.9 Hz, 1H, NCH), 7.98 (s, 1H, ArH, triazole), 8.14 (s, 1H, ArH, triazole). ^13^C-NMR (DMSO-*d~6~*): δ = 36.3 (CH~2~NC=O), 44.1 (CH~2~NC=O), 52.4 (NCH~2~Ph), 52.6 (NCH~2~Ph), 101.0 (CH), 124.2 (ArCH, triazole), 124.5 (ArCH, triazole), 129.27 (2×ArCH), 129.30 (2×ArCH), 130.46 (2×ArCH), 130.49 (2×ArCH), 133.38 (C~ipso~), 133.44 (C~ipso~), 135.4 (C~ipso~), 135.5 (C~ipso~), 143.0 (C~ipso~, triazole), 143.4 (C~ipso~, triazole), 144.9 (NCH), 151.3 (N~2~C=O), 162.6 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,128, 3,064, 3,013, 2,970, 2,951, 1,702 (C=C), 1,655 (NC=O, N~2~C=O), 1,542, 1,491, 1,453. HRMS (ESI-TOF) calculated for C~24~H~20~Cl~2~N~8~O~2~+H^+^: 523.1159; Found: 523.1158.

*1,3-Bis((1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione* (**8**). The procedure described above (using the same quantities of Cu(OAc)~2~•H~2~O, 1,10-phenanthroline monohydrate, sodium L-ascorbate) was followed to obtain compound **8**, employing **3** (100 mg, 0.53 mmol), NaN~3~ (76 mg, 1.17 mmol) and 4-bromobenzyl bromide (292 mg, 1.17 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/EtOH 97:3 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 288 mg (87% yield) of the desired product **8** as a white solid, m.p. 196--198 °C. ^1^H-NMR (DMSO-*d~6~*): δ = 4.96 (s, 2H, CH~2~NC=O), 4.98 (s, 2H, CH~2~NC=O), 5.49 (s, 2H, NCH~2~Ph), 5.53 (s, 2H, NCH~2~Ph), 5.73 (d, *J* = 7.9 Hz, 1H, CH), 7.21 (d, *J* = 8.4 Hz, 2H, ArH), 7.23 (d, *J* = 8.3 Hz, 2H, ArH), 7.53 (d, *J* = 8.3 Hz, 2H, ArH), 7.54 (d, *J* = 8.4 Hz, 2H, ArH), 7.80 (d, *J* = 7.9 Hz, 1H, NCH), 7.98 (s, 1H, ArH, triazole), 8.13 (s, 1H, ArH, triazole). ^13^C-NMR (DMSO-*d~6~*): δ = 36.3 (CH~2~NC=O), 44.1 (CH~2~NC=O), 52.5 (NCH~2~Ph), 52.6 (NCH~2~Ph), 101.0 (CH), 121.9 (C~ipso~), 122.0 (C~ipso~), 124.2 (ArCH, triazole), 124.5 (ArCH, triazole), 130.76 (2×ArCH), 130.79 (2×ArCH), 132.21 (2×ArCH), 132.23 (2×ArCH), 135.8 (C~ipso~), 135.9 (C~ipso~), 143.0 (C~ipso~, triazole), 143.4 (C~ipso~, triazole), 144.9 (NCH), 151.2 (N~2~C=O), 162.5 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,141, 3,128, 3,073, 1,703 (C=C), 1,656 (NC=O, N~2~C=O), 1,593, 1,543, 1,488, 1,455. HRMS (ESI-TOF) calculated for C~24~H~20~Br~2~N~8~O~2~+H^+^: 611.0148; Found: 611.0150.

*1,3-Bis((1-(4-iodobenzyl)-1H-1,2,3-triazol-4-yl)methyl)pyrimidine-2,4(1H,3H)-dione* (**9**). The procedure described above (using the same quantities of Cu(OAc)~2~•H~2~O, 1,10-phenanthroline mono-hydrate, sodium L-ascorbate) was followed to obtain compound **9**, employing **3** (100 mg, 0.53 mmol), NaN~3~ (76 mg, 1.17 mmol) and 4-iodobenzyl bromide (365 mg, 1.23 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/MeOH 90:10 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 315 mg (84% yield) of the desired product **9** as a white solid, m.p. 202--204 °C. ^1^H-NMR (DMSO-*d*~6~): δ = 4.95 (s, 2H, CH~2~NC=O), 4.97 (s, 2H, CH~2~NC=O), 5.46 (s, 2H, NCH~2~Ph), 5.50 (s, 2H, NCH~2~Ph), 5.73 (d, *J* = 7.9 Hz, 1H, CH), 7.06 (d, *J* = 8.2 Hz, 2H, ArH), 7.07 (d, *J* = 8.2 Hz, 2H, ArH), 7.69 (d, *J* = 8.2 Hz, 2H, ArH), 7.70 (d, *J* = 8.3 Hz, 2H, ArH), 7.79 (d, *J* = 7.9 Hz, 1H, NCH), 7.95 (s, 1H, ArH, triazole), 8.12 (s, 1H, ArH, triazole). ^13^C-NMR (DMSO-*d~6~*): δ = 36.3 (CH~2~NC=O), 44.1 (CH~2~NC=O), 52.6 (NCH~2~Ph), 52.8 (NCH~2~Ph), 95.02 (C~ipso~), 95.08 (C~ipso~), 101.0 (CH), 124.1 (ArCH, triazole), 124.5 (ArCH, triazole), 130.81 (2×ArCH), 130.83 (2×ArCH), 136.2 (C~ipso~), 136.3 (C~ipso~), 138.06 (2×ArCH), 138.08 (2×ArCH), 143.0 (C~ipso~, triazole), 143.4 (C~ipso~, triazole), 144.9 (NCH), 151.2 (N~2~C=O), 162.5 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,127, 3,074, 3,011, 2,944, 1,703 (C=C), 1,654 (NC=O, N~2~C=O), 1,588, 1,544, 1,484, 1,453. HRMS (ESI-TOF) calculated for C~24~H~20~I~2~N~8~O~2~+H^+^: 706.9871; Found: 706.9851.

*1,3-Bis((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidine-2,4(1H,3H)-dione* (**10**). The procedure described above was followed to obtain compound **10**, employing Cu(OAc)~2~•H~2~O (4.5 mg, 0.025 mmol), 1,10-phenanthroline monohydrate (5 mg, 0.025 mmol), sodium L-ascorbate (99 mg, 0.5 mmol), **4** (100 mg, 0.49 mmol), NaN~3~ (70 mg, 1.08 mmol) and benzyl chloride (0.12 mL, 1.08 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/EtOH 98:2 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 148 mg (64% yield) of the desired product **10** as a white solid, m.p. 187--189 °C. ^1^H-NMR (CDCl~3~): δ = 1.86 (d, *J* = 1.0 Hz, 3H, CH~3~), 4.91 (s, 2H, CH~2~NC=O), 5.16 (s, 2H, CH~2~NC=O), 5.43 (s, 2H, NCH~2~Ph), 5.46 (s, 2H, NCH~2~Ph), 7.21--7.28 (m, 4H, ArH), 7.29 (d, *J* = 1.1 Hz, 1H, NCH), 7.30--7.37 (m, 6H, ArH), 7.49 (s, 1H, ArH, triazole), 7.62 (s, 1H, ArH, triazole). ^13^C-NMR (CDCl~3~): δ = 13.0 (CH~3~), 36.4 (CH~2~NC=O), 43.9 (CH~2~NC=O), 54.2 (NCH~2~Ph), 54.4 (NCH~2~Ph), 110.3 (CCH~3~), 123.5 (ArCH, triazole), 123.7 (ArCH, triazole), 128.2 (2×ArCH), 128.4 (2×ArCH), 128.8 (ArCH), 129.0 (ArCH), 129.1 (2×ArCH), 129.3 (2×ArCH), 134.3 (C~ipso~), 134.7 (C~ipso~), 138.7 (NCH), 142.6 (C~ipso~, triazole), 143.5 (C~ipso~, triazole), 151.2 (N~2~C=O), 163.5 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,133, 3,115, 3,068, 2,956, 1,697 (C=C), 1,672 (NC=O), 1,646 (N~2~C=O), 1,550, 1,496, 1,453, 1,432. HRMS (ESI-TOF) calculated for C~25~H~24~N~8~O~2~+H^+^: 469.2094; Found: 469.2096.

*1,3-Bis((1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidine-2,4(1H,3H)-dione* (**11**). The procedure described above was followed to obtain compound **11**, employing Cu(OAc)~2~•H~2~O (4.5 mg, 0.025 mmol), 1,10-phenanthroline monohydrate (5 mg, 0.025 mmol), sodium L-ascorbate (99 mg, 0.5 mmol), **4** (100 mg, 0.49 mmol), NaN~3~ (70 mg, 1.08 mmol) and 4-fluorobenzyl chloride (0.13 mL, 1.08 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/MeOH 90:10 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 216 mg (87% yield) of the desired product **11** as a white solid, m.p. 170--172 °C. ^1^H-NMR (DMSO-*d*~6~): δ = 1.77 (d, *J* = 1.0 Hz, 3H, CH~3~), 4.92 (s, 2H, CH~2~NC=O), 4.99 (s, 2H, CH~2~NC=O), 5.49 (s, 2H, NCH~2~Ph), 5.53 (s, 2H, NCH~2~Ph), 7.13--7.19 (m, 4H, ArH), 7.31--7.37 (m, 4H, ArH), 7.69 (d, *J* = 1.1 Hz, 1H, NCH), 7.96 (s, 1H, ArH, triazole), 8.12 (s, 1H, ArH, triazole). ^13^C-NMR (DMSO-*d~6~*): δ = 13.1 (CH~3~), 36.6 (CH~2~NC=O), 44.0 (CH~2~NC=O), 52.4 (NCH~2~Ph), 52.5 (NCH~2~Ph), 108.6 (CCH~3~), 116.0 (d, *J*^2^~CF~ = 21.4 Hz, 2×ArCH), 116.2 (d, *J*^2^~CF~ = 21.4 Hz, 2×ArCH), 124.0 (ArCH, triazole), 124.3 (ArCH, triazole), 130.8 (d, *J*^3^~CF~ = 8.8 Hz, 2×ArCH), 130.9 (d, *J*^3^~CF~ = 8.8 Hz, 2×ArCH), 132.7 (d, *J*^4^~CF~ = 2.5 Hz, C~ipso~), 132.8 (d, *J*^4^~CF~ = 2.5 Hz, C~ipso~), 140.7 (NCH), 143.1 (C~ipso~, triazole), 143.5 (C~ipso~, triazole), 151.1 (N~2~C=O), 161.4 (d, *J*~CF~ = 245.1 Hz, C~ipso~), 163.3 (NC=O), 163.4 (d, *J*~CF~ = 245.1 Hz, C~ipso~). FT-IR/ATR ν~max~ cm^−1^: 3,133, 3,073, 3,012, 2,954, 1,694, 1,664, 1,641, 1,605, 1,510, 1,463, 1,435. HRMS (ESI-TOF) calculated for C~25~H~22~F~2~N~8~O~2~+H^+^: 505.1906; Found: 505.1916.

*1,3-Bis((1-(4-chlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidine-2,4-(1H,3H)-dione* (**12**). The procedure described above was followed to obtain compound **12**, employing 4.5 mg (0.025 mmol) of Cu(OAc)~2~•H~2~O, 1,10-phenanthroline monohydrate (5 mg, 0.025 mmol), sodium L-ascorbate (99 mg, 0.5 mmol), **4** (100 mg, 0.49 mmol), NaN~3~, (70 mg, 1.08 mmol) and 4-chlorobenzyl chloride (184 mg, 1.14 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/EtOH 97:3 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 198 mg (74% yield) of the desired product **12** as a white solid, m.p. 154--156 °C. ^1^H-NMR (CDCl~3~): δ = 1.87 (d, *J* = 1.1 Hz, 3H, CH~3~), 4.91 (s, 2H, CH~2~NC=O), 5.17 (s, 2H, CH~2~NC=O), 5.41 (s, 2H, NCH~2~Ph), 5.44 (s, 2H, NCH~2~Ph), 7.17 (d, *J* = 8.5 Hz, 2H, ArH), 7.21 (d, *J* = 8.5 Hz, 2H, ArH), 7.29 (d, *J* = 1.1 Hz, 1H, NCH), 7.30 (d, *J* = 8.5 Hz, 2H, ArH), 7.33 (d, *J* = 8.5 Hz, 2H, ArH), 7.50 (s, 1H, ArH, triazole), 7.64 (s, 1H, ArH, triazole). ^13^C-NMR (CDCl~3~): δ = 13.0 (CH~3~), 36.3 (CH~2~NC=O), 44.1 (CH~2~NC=O), 53.4 (NCH~2~Ph), 53.6 (NCH~2~Ph), 110.3 (CCH~3~), 123.5 (ArCH, triazole), 123.7 (ArCH, triazole), 129.3 (2×ArCH), 129.5 (2×ArCH), 129.6 (2×ArCH), 129.7 (2×ArCH), 132.8 (C~ipso~), 133.1 (C~ipso~), 134.8 (C~ipso~), 135.1 (C~ipso~), 138.7 (NCH), 142.8 (C~ipso~, triazole), 143.7 (C~ipso~, triazole), 151.2 (N~2~C=O), 163.5 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,142, 3,121, 3,068, 3,012, 2,955, 2,925, 1,693 (C=C), 1,662 (NC=O), 1,637 (N~2~C=O), 1,491, 1,462, 1,433. HRMS (ESI-TOF) calculated for C~25~H~22~Cl~2~N~8~O~2~+H^+^: 537.1315; Found: 537.1323.

*1,3-Bis((1-(4-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidine-2,4-(1H,3H)-dione* (**13**). The procedure described above was followed to obtain compound **13**, employing Cu(OAc)~2~•H~2~O (4.5 mg, 0.025 mmol), 1,10-phenanthroline monohydrate (5 mg, 0.025 mmol), sodium L-ascorbate (99 mg, 0.5 mmol), **4** (100 mg, 0.49 mmol), NaN~3~ (70 mg, 1.08 mmol) and 4-bromobenzyl bromide (270 mg, 1.08 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/EtOH 97:3 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 225 mg (73% yield) of the desired product **13** as a white solid, m.p. 148--150 °C. ^1^H-NMR (CDCl~3~): δ = 1.87 (d, *J* = 1.2 Hz, 3H, CH~3~), 4.91 (s, 2H, CH~2~NC=O), 5.16 (s, 2H, CH~2~NC=O), 5.39 (s, 2H, NCH~2~Ph), 5.42 (s, 2H, NCH~2~Ph), 7.10 (d, *J* = 8.6 Hz, 2H, ArH), 7.15 (d, *J* = 8.6 Hz, 2H, ArH), 7.29 (d, *J* = 1.2 Hz, 1H, NCH), 7.46 (d, *J* = 8.5 Hz, 2H, ArH), 7.49 (d, *J* = 8.5 Hz, 2H, ArH), 7.50 (s, 1H, ArH, triazole), 7.65 (s, 1H, ArH, triazole). ^13^C-NMR (CDCl~3~): δ = 13.0 (CH~3~), 36.3 (CH~2~NC=O), 44.1 (CH~2~NC=O), 53.5 (NCH~2~Ph), 53.7 (NCH~2~Ph), 110.3 (CCH~3~), 122.9 (C~ipso~), 123.2 (C~ipso~), 123.5 (ArCH, triazole), 123.7 (ArCH, triazole), 129.9 (2×ArCH), 130.0 (2×ArCH), 132.3 (2×ArCH), 132.4 (2×ArCH), 133.3 (C~ipso~), 133.7 (C~ipso~), 138.7 (NCH), 142.8 (C~ipso~, triazole), 143.7 (C~ipso~, triazole), 151.2 (N~2~C=O), 163.4 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,139, 3,101, 3,069, 2,998, 2,953, 2,922, 1,693 (C=C), 1,661 (NC=O), 1,637 (N~2~C=O), 1,488, 1,462, 1,432. HRMS (ESI-TOF) calculated for C~25~H~22~Br~2~N~8~O~2~+H^+^: 625.0305; Found: 625.0311.

*1,3-Bis((1-(4-iodobenzyl)-1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidine-2,4-(1H,3H)-dione* (**14**). The procedure described above was followed to obtain compound **14**, employing Cu(OAc)~2~•H~2~O (4.5 mg, 0.025 mmol), 1,10-phenanthroline monohydrate (5 mg (0.025 mmol), sodium L-ascorbate (99 mg, 0.5 mmol), **4** (100 mg, 0.49 mmol), NaN~3~ (70 mg, 1.08 mmol) and 4-iodobenzyl bromide (339 mg, 1.14 mmol). The crude product was purified by column chromatography (CH~2~Cl~2~/MeOH 90:10 *v*/*v*) and recrystallized from CH~2~Cl~2~/hexane (1:1 *v*/*v*) to afford 305 mg (86% yield) of the desired product **14** as a white solid, m.p. 229--231 °C. ^1^H-NMR (DMSO-*d*~6~): δ = 1.77 (s, 3H, CH~3~), 4.92 (s, 2H, CH~2~NC=O), 4.99 (s, 2H, CH~2~NC=O), 5.46 (s, 2H, NCH~2~Ph), 5.50 (s, 2H, NCH~2~Ph), 7.06 (d, *J* = 7.7 Hz, 2H, ArH), 7.07 (d, *J* = 7.7 Hz, 2H, ArH), 7.68--7.71 (m, 5H, NCH, ArH), 7.95 (s, 1H, ArH, triazole), 8.11 (s, 1H, ArH, triazole). ^13^C-NMR (DMSO-*d~6~*): δ = 13.1 (CH~3~), 36.6 (CH~2~NC=O), 44.0 (CH~2~NC=O), 52.6 (NCH~2~Ph), 52.8 (NCH~2~Ph), 95.01 (C~ipso~), 95.07 (C~ipso~), 108.6 (CCH~3~), 124.1(ArCH, triazole), 124.4 (ArCH, triazole), 130.81 (2×ArCH), 130.82 (2×ArCH), 136.2 (C~ipso~), 136.3 (C~ipso~), 138.05 (2×ArCH), 138.08 (2×ArCH), 140.7 (NCH), 143.1 (C~ipso~, triazole), 143.5 (C~ipso~, triazole), 151.1 (N~2~C=O), 163.3 (NC=O). FT-IR/ATR ν~max~ cm^−1^: 3,138, 3,119, 3,072, 2,957, 1,696, 1,640, 1,590, 1,555, 1,464. HRMS (ESI-TOF) calculated for C~25~H~22~I~2~N~8~O~2~+H^+^: 721.0028; Found: 721.0019.

4. Conclusions
==============

Ten new triazole derivatives of the pyrimidine bases uracil and thymine which are potential corrosion inhibitors of steel in acidic media were synthesized in good yields, employing a "click" multicomponent reaction.
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